Skip to main content
Clinical Trials/NCT06693193
NCT06693193
Not yet recruiting
Not Applicable

Personalized Virtual Environments for Patients with Cognitive Impairment Exhibiting Responsive Behaviors: Proof-of-Concept and Feasibility Study

Fondazione Bruno Kessler1 site in 1 country10 target enrollmentJanuary 2025

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cognitive Impairment
Sponsor
Fondazione Bruno Kessler
Enrollment
10
Locations
1
Primary Endpoint
Feasibility based on the health staff operator perspective using the System Usability Scale (SUS)
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this feasibility study is to explore the feasibility of using realistic, customizable virtual reality (VR) environments in response to the onset of Responsive Behaviors in elderly residents with cognitive impairment.

Specifically, the study will assess;

  • feasibility through acceptance metrics (including recruitment rate, adherence rate, attrition rate, and tolerance to the intervention);
  • safety (monitoring for adverse effects related to VR headset use);
  • user engagement, enjoyment, and overall experience.

Participants will be exposed to three VR sessions conducted before, during, or after a situation deemed activating (e.g., personal hygiene activities). Operators will conduct a baseline assessment to identify specific moments when the participant experiences responsive behaviors. Additionally, operators may administer the Oculus VR headset when responsive behaviors occur outside of baseline-identified moments.

Detailed Description

Study Site and Environment: Data collection will occur at the Azienda Pubblica di Servizi alla Persona "Margherita Grazioli" in Povo, Trento. The experimental setup will be free from external interference to minimize distractions and ensure a smooth study process. The study will be conducted in familiar, ecologically relevant settings within APSP, selecting environments likely to stimulate activation states in participants. Duration and Procedure: The study is expected to last six months. Each participant will undergo at least three VR sessions about situations that may trigger activation, such as personal hygiene activities. A baseline assessment will pinpoint specific times when participants exhibit responsive behaviors. Additionally, VR sessions may be initiated if responsive behaviors arise outside the predicted times using the Oculus headset. Procedure and Timing for Each VR Session: Preliminary Assessment (Participant Selection) (\~30 minutes): Participants are selected based on inclusion/exclusion criteria and provided with informed consent. Information is collected from clinical records and updated based on the participant's condition. An initial assessment examines responsive behaviors' type, frequency, and timing using demographic information, FAST, NPI, and CMAI. Pre-Session Evaluation (T0) (\~15 minutes): Assessments include pain, responsive behaviors, emotions, anxiety, pleasantness, and discomfort before VR use (using PAINAD and STAI-Y1). Virtual Environment Selection (\~5 minutes): The operator selects the VR environment for the participant through a smartphone linked to the Oculus headset via WiFi. Procedure Explanation and Contextualization (\~5 minutes): A brief overview of the session and VR setup is provided to the participant. Familiarization with Oculus Headset (\~1-2 minutes): A brief period to help the participant acclimate to the VR headset. VR Session and During-Session Evaluation (T1) (\~8 minutes within tolerance): The VR session is audio-visual recorded, with the operator noting participant behaviors and responses (using OERS, Observation Sheet, STAI-Y1, Ad Hoc Questionnaire, PAINAD, and DataSheet2). Post-Session Evaluation (T2) (\~15 minutes): Pain, responsive behaviors, emotions, anxiety, pleasantness, and discomfort are re-evaluated (using PAINAD, DataSheet2, Ad Hoc Questionnaire, STAI-Y1, OERS, NPT-ES, and VRSQ). Final Evaluation (T3) (\~10 minutes): After all sessions, a final assessment using the Cohen-Mansfield Agitation Inventory (CMAI) is conducted.

Registry
clinicaltrials.gov
Start Date
January 2025
End Date
September 2025
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Fondazione Bruno Kessler
Responsible Party
Principal Investigator
Principal Investigator

Susanna Pardini

Researcher

Fondazione Bruno Kessler

Eligibility Criteria

Inclusion Criteria

  • Adults over 18 years of age.
  • Native Italian speakers.
  • Can provide written informed consent for study participation or have a legal guardian who can give consent on their behalf.

Exclusion Criteria

  • Presence of any psychiatric diagnoses as recorded in medical records.
  • A total score of ≥ 40 on the Neuropsychiatric Inventory (NPI) indicates neuropsychiatric symptoms.
  • A partial NPI score \> 6 in the domains of agitation/aggression or delusions.
  • Enrollment in palliative care services.
  • Severe neurological damage, a positive diagnosis of epilepsy, or having first-degree relatives diagnosed with epilepsy.
  • Presence of a cardiac pacemaker or other metallic devices.
  • Infectious or gastrointestinal disorders.
  • Open facial wounds, motor or visual impairments, or neuromuscular pain that would prevent using the Oculus VR headset.
  • Refusal to consent, either by the individual or their legal representative, for study participation.

Outcomes

Primary Outcomes

Feasibility based on the health staff operator perspective using the System Usability Scale (SUS)

Time Frame: From enrollment to the end of treatment at 3 weeks

The SUS scale permitted the obtaining of information about the system's usability. The SUS range raw score from 0 to 100.

Feasibility using an Ad-hoc questionnaire

Time Frame: From enrollment to the end of treatment at 3 weeks

The ad-hoc questionnaire permitted information about usability, engagement, satisfaction, and pleasure during exposure to the VR environment, as well as feelings and relaxation. The questionnaire is composed of 30 items based on a Likert scale from 1 to 5 (range score from 0 to 4), 15 items based on a Likert scale from 1 to 4 (range score from 0 to 3), and five open-ended questions.

Feasibility using the Non-pharmacological Therapy Experience Scale (NPT-ES)

Time Frame: From enrollment to the end of treatment at 3 weeks

The NPT-ES permitted obtaining information about the subjective experience during the administration of non-pharmacological therapy. Five items are assessed on a Likert scale from 0 to 3. The total raw score is from 0 to 15.

Feasibility based on the health staff operator perspective using Focus Groups

Time Frame: From enrollment to the end of treatment at 3 weeks

Secondary Outcomes

  • Assessment of the Responsive Behaviors administering the COHEN MANSFIELD - AGITATION INVENTORY (CMAI)(From enrollment to the end of treatment at 3 weeks)
  • Assessment of the Responsive Behaviors administering the Functional Assessment Staging Tool (FAST)(From enrollment to the end of treatment at 3 weeks)
  • Investigation of Adverse Symptoms Associated with Exposure to the Virtual Reality Device using the Virtual Reality Symptoms Questionnaire (VRSQ)(From enrollment to the end of treatment at 3 weeks)
  • Assessment of the pharmacotherapy administration and the users'behaviors before or during the VR sessions using the DataSheet 2(From enrollment to the end of treatment at 3 weeks)
  • Pain experience assessment using the Pain Assessment in Advanced Dementia (PAINAD)(From enrollment to the end of treatment at 3 weeks)
  • Assessment of the state-anxiety using the State-Trait Anxiety Inventory-Y1 (STAI-Y1)(From enrollment to the end of treatment at 3 weeks)
  • Emotional and behavioral assessment using the Observed Emotion Rating Scale (OERS)(From enrollment to the end of treatment at 3 weeks)

Study Sites (1)

Loading locations...

Similar Trials